Moss, 1 November 2021
Gentian Diagnostics ASA is pleased to announce that the results from a study conducted in collaboration with Charité – Universitätsmedizin Berlin and Labor Berlin have been presented as a poster at the European Society for Emergency Medicine (EUSEM) congress in Lisbon.
The results are part of an ongoing prospective clinical trial (CASCADE) which is performed in the Emergency department of the Charité – Universitätsmedizin Berlin Campus Benjamin Franklin.
The study concluded that the calprotectin levels in plasma were significantly higher in ventilated than in non-ventilated COVID-19 patients. Moreover, calprotectin was able to predict need for Intensive Care Unit (ICU) admission with outstanding performance and an AUROC of 1.0. The performance of calprotectin in prediction of ICU admission was better than performance of the biomarker procalcitonin.
10 COVID-19 patients with positive SARS-CoV-2 PCR test were enrolled and the value of calprotectin in prediction of need for admission to ICU and the need for mechanical ventilation was also investigated. The conclusion from this study supports calprotectin as an early biomarker for risk stratification and optimal management of COVID-19 patients. Early identification of patients with severe form of the disease is of critical importance for optimal patient care and use of healthcare resources.
The authors also confirm that use of Gentian’s calprotectin assay GCAL® supports an easily accessible and efficient measurement of calprotectin in routine laboratories. For further information please see the enclosed poster.
About Gentian Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.